Balchem Co. Expected to Earn Q2 2025 Earnings of $1.04 Per Share (NASDAQ:BCPC)

Balchem Co. (NASDAQ:BCPC) – Stock analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Balchem in a note issued to investors on Monday, May 6th. HC Wainwright analyst R. Selvaraju anticipates that the basic materials company will post earnings of $1.04 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $170.00 target price on the stock. The consensus estimate for Balchem’s current full-year earnings is $4.10 per share. HC Wainwright also issued estimates for Balchem’s Q4 2025 earnings at $1.12 EPS.

Balchem (NASDAQ:BCPC) last posted its quarterly earnings data on Friday, February 16th. The basic materials company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.02. Balchem had a return on equity of 11.03% and a net margin of 12.35%. The firm had revenue of $228.70 million for the quarter, compared to analysts’ expectations of $234.66 million. During the same period in the previous year, the firm earned $0.66 EPS. The business’s quarterly revenue was down 1.6% on a year-over-year basis.

Separately, StockNews.com downgraded shares of Balchem from a “buy” rating to a “hold” rating in a report on Thursday, April 25th.

Balchem Trading Down 1.4 %

BCPC stock opened at $153.28 on Wednesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.61 and a quick ratio of 1.72. Balchem has a 1-year low of $110.74 and a 1-year high of $159.52. The business has a 50 day simple moving average of $150.98 and a two-hundred day simple moving average of $141.30. The company has a market capitalization of $4.97 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 3.33 and a beta of 0.72.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Balchem by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 3,791,512 shares of the basic materials company’s stock worth $563,987,000 after acquiring an additional 30,868 shares in the last quarter. Conestoga Capital Advisors LLC grew its stake in Balchem by 3.9% in the first quarter. Conestoga Capital Advisors LLC now owns 1,125,384 shares of the basic materials company’s stock worth $174,378,000 after purchasing an additional 42,172 shares in the last quarter. Geneva Capital Management LLC increased its holdings in Balchem by 0.5% during the 4th quarter. Geneva Capital Management LLC now owns 767,211 shares of the basic materials company’s stock worth $114,123,000 after purchasing an additional 3,885 shares during the period. Dimensional Fund Advisors LP raised its position in Balchem by 1.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 687,485 shares of the basic materials company’s stock valued at $102,265,000 after purchasing an additional 11,629 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its holdings in shares of Balchem by 0.5% in the 4th quarter. Clearbridge Investments LLC now owns 521,590 shares of the basic materials company’s stock worth $77,587,000 after buying an additional 2,801 shares during the period. Institutional investors own 87.91% of the company’s stock.

Insider Transactions at Balchem

In related news, CAO William A. Backus sold 7,000 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $155.19, for a total value of $1,086,330.00. Following the sale, the chief accounting officer now owns 5,914 shares in the company, valued at $917,793.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Michael Robert Sestrick sold 11,100 shares of the stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $153.21, for a total transaction of $1,700,631.00. Following the sale, the senior vice president now owns 6,736 shares in the company, valued at approximately $1,032,022.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO William A. Backus sold 7,000 shares of Balchem stock in a transaction on Monday, February 26th. The stock was sold at an average price of $155.19, for a total transaction of $1,086,330.00. Following the transaction, the chief accounting officer now directly owns 5,914 shares of the company’s stock, valued at $917,793.66. The disclosure for this sale can be found here. Insiders have sold 76,630 shares of company stock valued at $11,843,249 in the last ninety days. Corporate insiders own 1.77% of the company’s stock.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.